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Deep learning (DL) is a relatively newer subdomain of machine learning (ML) with incredible potential for
certain applications in the medical field. Given recent advances in its use in neuro-oncology, its role in
diagnosing, prognosticating, and managing the care of cancer patients has been the subject of many research
studies. The gamut of studies has shown that the landscape of algorithmic methods is constantly improving
with each iteration from its inception. With the increase in the availability of high-quality data, more training
sets will allow for higher fidelity models. However, logistical and ethical concerns over a prospective trial
comparing prognostic abilities of DL and physicians severely limit the ability of this technology to be widely
adopted. One of the medical tenets is judgment, a facet of medical decision making in DL that is often missing
because of its inherent nature as a “black box.” A natural distrust for newer technology, combined with a lack of
autonomy that is normally expected in our current medical practices, is just one of several important limitations
in implementation. In our review, we will first define and outline the different types of artificial intelligence
(AI) as well as the role of AI in the current advances of clinical medicine. We briefly highlight several of the
salient studies using different methods of DL in the realm of neuroradiology and summarize the key findings
and challenges faced when using this nascent technology, particularly ethical challenges that could be faced by
users of DL.
Keywords: Deep learning, Glioma prognostication, Machine learning, Neuro-oncology

INTRODUCTION
Amidst contemporary shifts in the global “smart-tech” arena, there has been a parallel shift
in the dynamics of technological integration in health care and its rapidly growing role in
supplementing traditional methods of patient care.[36] An integral aspect of this global movement
is the marriage of artificial intelligence (AI) with vast databases as a tool to assist physicians to
not only diagnose but also subsequently manage the ever-growing burden of disease.
The realm of AI contains within itself machine learning (ML), as well as a further subset known
as deep learning (DL). ML takes use of statistical models to enable these algorithms to improve
as more data are introduced to them [Figure 1].[28] DL is also a process by which computers glean
patterns from past experiences and large amounts of data to generate algorithms designed to
make increasingly accurate predictions about future events.[3,5] What further specializes it from
ML is the multilayered neural networks used to train on vast amounts of data. Neural networks
much like the brain use nodes of information (neurons) that are arranged in layers. Each
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probable to rule in the disease (at the same specificity).[30]
Other applications include but are not limited to the ability to
predict genomic features such as clinically relevant mutations,
to predict and build models of regulatory and enhancing
elements in the DNA replication and transcription, and to
predict patterns of disease based on population statistics such
as infectious disease epidemics and pandemics.[38]

Figure 1: The subsets of artificial intelligence.

neuron uses data from the training set (or previous neuronal
connections) and calculates a new piece of datum using
weightage and bias factors before communicating the new
piece to neuron(s) in the next layer, eventually generating an
outcome.[39]
DL algorithms may then function when provided sets of
parameters to evaluate a plethora of aspects of clinical
importance in medicine, including screening, diagnosis,
and treatment efficacy. Each algorithm must first be assessed
by the relevant performance metrics of the extracted
patterns when extrapolating beyond the model dataset.[39]
In practice, however, the presence of unknown confounders
and imprecise measurements endows a random component
to our estimates that varies from individual to individual
and population to population.[5] As a result, the diversity
of a training dataset will enable the DL algorithm to learn
“better,” which, in turn, would allow for greater and more
valid generalizability of predicted patterns on a wider range
of populations.[5,39]
Consequently, this generalizability requires a revolution in
data mining to generate large volumes of data from which
this subset of AI technology can learn. This is vital to
overcome the challenges of data sparsity, multicollinearity,
and overfitting, and therefore, to effectively minimize
internal bias in the model developed.[38]
Based on a subtle balance between use and limitations, DL
promises to play a crucial role in healthcare, allowing us
to find a niche between generalized practice guidelines
and personalized patient-centric care. These algorithms
have already shown a high level of diagnostic performance
based on imaging data for conditions including diabetic
retinopathy, skin cancer, and pneumonia.[36] Salim et al.,
for example, have recently commented on the rates of
diagnostic capabilities of AI (92% area under the receiver
operating curve [AUROC] for three different commercially
available computer-aided detection [CADe] algorithms) in
assessments of screening mammograms, with one algorithm
demonstrating comparable sensitivity (81.9%) to those of
first-reader (77.4%) and second-reader (80.1%) radiologists
given that the AI and radiologists’ readings were equally
Surgical Neurology International • 2021 • 12(435)
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Amidst these enhancements in health care across disciplines,
the realm of prediction and management in oncology stands
to benefit greatly from such technologies.[26] In 2014, Louis
et al. published an update on behalf of the International
Society of Neuropathology stating that non‐tissue‐based
information (e.g. clinical and radiological information),
could be of clear utility to aid in reaching a diagnosis. This
support from an international body has led neuroradiology
to play an increasingly important role in the potential
treatment of neuro-oncological patients, with promises of
AI-enhanced readings further elevating the importance of
neuroradiology.[24] As such, our paper, as summarized in
[Figure 2], aims to assess the state of DL algorithms in their
efficacy and precision of pre-, peri-, and post-operative
decision-making in neuro-oncology, using gliomas as an
oncologic model.

DIAGNOSIS, GRADING, AND CLASSIFICATION
OF GLIOMAS
The clinical course of a neoplasm is dependent on the
efficacy of several stages of medical intervention including
the recognition of clinical manifestations, initial screening
of the lesion (employing imaging or laboratory testing), the
decision to observe or treat, postscreening histopathological
assessment/gold standard confirmation, and predicting
morbidity and mortality outcomes. ML can be used to aid
this paradigm of medical intervention at several of these
levels [Figure 3].[28]
As mentioned before, the strength of ML as a tool to evaluate
radiological screening independently or augmentatively
is yielding promising results, with this excitement not only
limited to mammography but also in the realms of lung
cancer, prostate cancer, and brain metastases with the use
of CADe and computer-aided diagnoses techniques.[2,7,35]
Prospectively, ML may be able to correlate radiological
imaging detailing the extent of disease with genomic data
of the lesion such as mutations and gene expressions and
histopathological findings to establish an accurate diagnosis
in an emerging field known as imaging genomics.[4]
The promise of ML in the field of oncology in addition
to the growing recognition of an integrated approach to
neuropathology lends optimism to the treatment of a subset
of neuro-oncological entities known as gliomas. These
tumors are difficult to render an exact judgment on, due to
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Figure 3: Levels of entry for deep learning applications in
neuro-oncology.

standard for the diagnosis of gliomas, the very notion of a
biopsy raises a few concerns. There are many inherent risks
with this method of diagnosis, with inevitable errors due to
inadequate sampling and time inefficiency.[43] Thus, the need
for elimination of subjectivity and improvement of sensitivity
and timeliness of histopathological diagnosis as well as
the growing logistical feasibility of ML imparts a growing
confidence in the use of such technology in the diagnosis of
gliomas.

Figure 2: The take-home message.

similarity of cellular structures among lower grade lesions;
with estimations varying due to inter-reader variability
depending on the professional experience of histopathologists
and radiologists, introducing an element of subjectivity.[37]
Although the simple grading of these tumors is not a principle
bottleneck in their treatment paradigm, some difficulties
remain in the presence of standardization efforts, such as the
use of objective classification criteria, the most prevalent of
which is the WHO classification.[34] Furthermore, although
histopathological and molecular analysis remains the gold

Broadly, ML techniques can be divided into those that learn
to predict outcomes based on input-output paired training,
termed supervised learning, or those that find patterns
within input data itself without preset outcomes, termed
unsupervised learning. Supervised learning itself can be
achieved through several techniques such as support vector
matrixes (SVMs) which aim to delineate a function that
separates two sets of data.[33]
Previously, studies have demonstrated that gliomas can be
classified according to their clinical grade using linear SVMs
which were trained on descriptive features such as amount of
mass effect of blood supply. The limitation of these studies,
such as one by Li et al., is that these quantitative features
were estimated by domain experts and the definition of
these features was limited to expert opinion and hence not
reproducible.[23] Two other studies subsequently used other
parametric features to improve accuracy; Devos et al. used
MR intensities with spectroscopy using linear discriminant
Surgical Neurology International • 2021 • 12(435)
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analysis, linear and nonlinear least squares SVMs (AUROC of
0.94 in distinguishing low-grade vs. high-grade gliomas),[11]
whereas Rajendran made use of association rule mining
(specifically pruned association rule), a technique in ML that
aims to predict certain characteristics of a set based on other
characteristics, to categorize CT scan brain images as simply
either normal, benign, or malignant with a 96% sensitivity
and 93% accuracy.[29]
It stands to reason from this discussion that the beginnings
of ML in neuropathology must be the generation of a dataset
from which newly developed AI can learn. For gliomas,
radiological evidence in addition to matched clinical, genetic,
and pathological data collections reside in the Cancer
Imaging Archive and Genomics Data Commons Data Portal
respectively, as a joint effort between the National Cancer
Institute and the National Human Genome Research Institute
from 2006 onward.[13] Since 2012, ML and DL techniques
applied to carefully selected data subsets from these archives
have already generated numerous algorithms related to
tumor segmentation (delineating the location and extension
of a lesion from surrounding tissue) under the brain tumor
segmentation challenge.
At present, algorithms generated by ML have shown promise
in accurate recognition of characteristics used to define
gliomas. Noninvasive neuroimaging tools for glioma grading
using a multitude of quantitative parameters obtained from
advanced magnetic resonance imaging (MRI) techniques,
such as dynamic contrast-enhanced MRI, arterial spin
labeling, and diffusion-weighted imaging, are currently being
utilized in many ML/DL models.[40] Skogen et al. were able
to discriminate high-grade gliomas from low-grade gliomas
using MRI texture analysis with a fine texture scale resulting
in a sensitivity and specificity of 93% and 81%, out of a total
of 95 glioma patients, but fared worse at differentiating
within those grades.[32]
The emerging field of radiogenomics breaks the restrictions of
applying AI technology to segmentation only. Advancement
in our understanding of key molecular differences in tumor
cells in comparison to normal cells and how these differences
drive changes in the microenvironment of the lesions now
lends itself to radiological patterns that can more accurately
identify a tumor. For example, certain glioma varieties
exhibit differences in isocitrate dehydrogenase (IDH), a
key enzyme in the Krebs cycle. Gliomas that potentiate
the activity of certain genotypes can drive the production
of 2-hydroxyglutaric acid, vascular endothelial growth
factor, and hypoxia-induced factor-1α. The activity of these
molecules may, in turn, produce characteristic radiological
findings such as alterations in histogram analysis.[21]
In fact, the current literature supports the idea of using
radiological imaging to predict the presence of such
biomolecular differences. Specifically in the context of
Surgical Neurology International • 2021 • 12(435)
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gliomas, studies have been conducted on IDH mutations,
O6-methylguanine
methyltransferase
(MGMT)
hypermethylation, epidermal growth factor receptors
(EGFRs), and 1p/19q chromosomal codeletions.
Zhang et al. were able to generate a predictive model for
IDH genotypes (of which genotypes 1 and 2 predict good
response to therapy) within high-grade glioma lesions based
on clinical data and radiological features obtained through
conventional MRI with an AUROC of 0.9231 in a validation
cohort.[41] The radiological features considered included
anatomical location, texture, and shape, among others. An
analogous non-AI-assisted study conducted by Zhou et al.
was also able to generate a similar algorithm to predict IDH1
mutation (AUROC 0.86 ± 0.01), 1p/19q codeletion status
(conferring increased survival) (AUROC of 0.96 ± 0.01), and
histological grade (AUROC 0.86 ± 0.01).[42] In contrast, a
convolution neural network (CNN), a form of DL especially
suited to image recognition, developed by Chang et al.
demonstrated a high degree of accuracy in predicting IDH
genotypes from MRI features in Grade II–IV gliomas in a
validation test (AUROC 0.95).[8] Chang et al. also developed
a neural network predictive of several factors, of which its
accuracy in predicting IDH1 mutation status was 94%.[9]
Similarly to IDH, MGMT hypermethylation is an important
identifying marker due that also happens to predict higher
response to treatment with combination temozolomide and
radiation.[17] Korfiatis et al. evaluated three residual deep
neural network architectures in their ability to predict the
MGMT methylation status. The three 18, 34, and 50 layered
architectures were able to achieve an accuracy of 76.75%
(±20.67%), 80.72% (±13.61%), and 94.90% (±3.92%),
respectively, lending credibility to higher-order processing
providing better results.[22] Similarly, Han and Kamdar obtained
a 67% accuracy on their validation set exploring MGMT
methylation status from MRI scans obtained from glioblastoma
multiforme (GBM) (Stage IV glioma) patients in the TCIA/
TCGA archives.[16] Chang et al. developed a neural network
from data for 259 patients from the TCIA/TCGA archives,
showing 83% accuracy in predicting methylation status.[9]
Other studies have also shown the ability of ML to detect
1p19q chromosomal codeletion (recognized as predictor
of chemotherapeutic response in gliomas), and EGFR
amplification status, another avenue for targeted therapy.
The aforementioned neural network developed by Chang
et al. manages to predict 1p19q codeletion status at an
accuracy of 92%.[9] A multiscale CNN developed by Akkus
et al. similarly predicts the codeletion at an 87.7% accuracy.[1]
Kickingereder et al. set out to use ML techniques to identify
a myriad of molecular characteristics including MGMT
hypermethylation and hallmark copy number variations. Of
these, they managed to develop a model that predicted EGFR
with a 63% accuracy.[21]
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With such exciting advancements, comparable outputs to
traditional methods of algorithmic generation, and a yet
unmet ceiling for improvement, it is thought that in the
near future, with the increasing availability of high-quality
data, CNNs will be the mainstay in both diagnosing and
prognosticating cancer, using widely available imaging
modalities.

PROGNOSIS PREDICTION
While ML can be useful in predicting prognosis based just
on imaging characteristics before surgery, we have more
information after surgical resection of the tumor that can
be incorporated in making extensive ML algorithms. Along
with imaging characteristics, the cumulative biopsy and
clinical data such as tumor markers can help generate ML
algorithms for estimating prognosis, complications, and other
outcomes. It can also overcome challenges such as the correct
recognition of tumor progression versus pseudoprogression,
a transient MRI finding mimicking progression with eventual
improvement. One such study aiming to delineate the two
conducted by Jang et al. developed a CNN model with an
AUROC of 83% that was trained on 59 individuals and tested
on 19 (Seoul National University Hospital dataset).[19] Repeat
model development by Jang et al. on the Korean Radiation
Oncology Data (n = 182) yielded a model with an AUROC
of 86%.[20] The necessity to develop a second model shall be
discussed in the section on ML and challenges.
Conventionally, prognosticating for GBM involves
accounting for a multitude of independent risk factors
impacting overall survival (OS) such as male gender, age
>60 years), poor preoperative Karnofsky scores of <70,
Caucasian ethnicity, advanced tumor with partial resection,
and surgery without adjuvant chemoradiation.[35] Using
several of these factors, Gittleman et al. developed an
independently validated nomogram with a concordance
index (equivalent to AUROC for the censored data used
in the study) of 0.657.[14] Notably, however, this study was
conducted on a Caucasian majority sample and utilizes
only MGMT hypermethylation as a prognostic factor of the
molecular characteristics seen in gliomas.
A study by Nie et al. demonstrated that through a 3D CNN,
they were able to train a support vector machine to predict a
long or short OS time. Their experimental results were able to
achieve 89.9% accuracy through their methods.[27] They were
able to feed single-channel (T1 MRI) multi-channel (fMRI
and DTI) data through a binary classifier (e.g. SVM) to
produce a framework for high-level brain tumor prognosis.
The study elucidates the incredible potential application
that a neural network possesses in prognosticating neurooncological patients based on just imaging alone. Similarly,
a study by Sanghani et al. was able to produce comparable
results on GBM patients based on routinely acquired MR

images alone. MR image derived texture features, tumor
shape, and volumetric features, and patient age was obtained
for 163 patients, which after put through a similar SVM, was
capable of producing 2-class and 3-class OS group prediction
accuracy of 98.7% and 88.95%, respectively.[31]
Another study by Zhou et al. utilized nonquantitative spatialcorrelated features from MRI defined tumor subregions
(termed habitats) in developing a computational framework.
This framework was able to use intratumoral grouping and
spatial mapping to identify GBM tumor subregions and
yield habitat-based features. After separating data sets into
those that underwent resection with GBM (32 patients), and
those that did not (22 patients), they were able to achieve
87.50% and 86.36% accuracies for survival group prediction,
respectively.[44]
The role of computational networks in prognosticating
overall long- and short-term survival is one that has been
evaluated through dozens of studies in low- to mid-grade
tumors, yielding similar results when applied to high-grade
tumors as well.[14,19,20,27,31,35,44] These networks are capable of
functioning on routinely acquired data, as demonstrated by
Sanghani et al., but also provide considerable information
to both the health-care provider and the patient. Eventually,
these systems are thought to be able to augment a neurooncologist’s decision-making ability, however, it would not
be long before they are potentially able to surpass human
performance in terms of prognostication.
CHALLENGES AND LIMITATIONS
Ethical considerations
ML, like any early adopted technology, is not without its
potential drawbacks in terms of ethical dilemmas.[10] ML
applied in other fields has already shown some biases, with
the problem stemming from the fact that algorithms may
mirror human biases. These biases may be introduced into
a medical setting where patients receive notably different
treatment regimes leading to an unoptimized approach and
potential harm.
There is an incredibly urgent need for ethical guidelines for
medical practitioners to use these advancing AI and machine
learning technologies. Time-constrained consultants are
expected to understand the inner workings of these insular
programs, as without knowing the data sets they are built
on, the technology can progress into a black box leading to
ethically gray outcomes. The lack of transparency inherent
with these systems may lead to physicians doubt either the
algorithm, or themselves, when their decision is conflicting
with one made by a machine.
It is also important to recall that the foundation of the
current medical system in many nations was based on a
Surgical Neurology International • 2021 • 12(435)
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patient-doctor relationship, not a patient-health-care system
relationship. Many doctors (and patients) feel uneasy at
the growing rate at which we are adopting these machines
into our health-care decisions. One study showed that over
63% of adults in the United Kingdom felt uncomfortable
with AI replacing the conventional decision-making
process.[12] Their lack of acceptance of AI is, to some degree,
warranted. In many fields, such as engineering, AI and ML
represent efficiency and will play an important role in the
future. However, one of the basic ethical tenets of medicine
is autonomy, which requires physicians to have a deeper
understanding of the clinical validation of ML in studies.
Health-care professionals operate on their own basis of
expertise and clinical acumen. When their decision-making
skills are infringed upon, by blindly accepting a prognosis,
diagnosis, or route of treatment provided by an AI or
algorithm, they could be seen as violating their Hippocratic
oath: primum non nocere (“first, do no harm”).[10] It is this
lack of transparency and explainability that is vital in the
role of medicine that limits its use when compared to its role
in business or engineering. Autonomy and nonmaleficence
are ethical principles grounded in “consequentialist”
ethical theory, which holds that the moral quality of an
action depends on its consequences. If the consequences of
choosing an AI favored diagnosis over a physician diagnosis,
whether for a high- or low-grade tumor, have the possibility
(however minute as shown by the accurate results of ML) of
resulting in an increased mortality – should we still use this
technology?[12]
Finally, the laws and rules of ethics are a worldwide debate
but enforced by national laws. Ethical laws on the potential of
AI and ML in medicine have been hotly contentious but are
virtually absent in low- and middle-income countries.[15] This
is not based on a lack of acceptance of AI/ML, as most healthcare professionals are in favor of their use (despite ethical
dilemmas), rather it is contingent on lack of infrastructure,
high cost, and lack of training in the region.[18]
Another reason for the impediment in widespread
adoption, and perhaps the most important one, is a lack
of accountability.[12] Allocation and grounds for liability
for adverse events related to the ML tools used with actual
patients need to be clarified by a national/international
ethical body. There is currently no conceivable method
to predict how these tools, along with other ML models in
medicine, will expose hospitals, physicians, and patients to
liability.
Other logistical drawbacks to the use of AI in medicine
include the scale of computational power required to develop
useful algorithms and prioritization of resource allocation
toward more pragmatic algorithms to maximize their effects.
Specifically in the field of radiological AI interpretations,
a major drawback in considering findings and pattern
Surgical Neurology International • 2021 • 12(435)
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recognition in any image modality is a lack of consensus
on which features would add most value to a preoperative
diagnosis, whether from a histogram parameters or image
texture attributes.[6] Attribute selection is a concept that
aims to remedy this challenge. It revolves around choosing a
division with the chosen least number of variables providing
the highest accuracy, alongside the most informative
attributes. The rigorous selection process searches through
possible combinations of attributes to find a particular
subset that can reliably predict outcomes, resulting in an
algorithm that is characterized by the method used to define
the predictive value of each subset of attributes (feature
evaluator) and the method determining the search over the
attributes (search method).[40]
A prospective trial on glioma patients, using a previously
trained CNN based on an accurate model, to help
prognosticate or diagnose a patient is sorely needed. Until,
we overcome challenges in implementation and their exact
use in clinical decision-making processes becomes apparent,
they will remain promising research ventures.

CONCLUSION
The use of AI to augment the clinical judgment and practice
of a physician is an exciting prospect, specifically in the
field of neuro-oncology where neuroradiology and neuroradiogenomics are prime candidates for the use of the
algorithmic learning in order. In a noninvasive manner, these
tools can predict the presence of several factors that can be
helpful in the diagnosis and prognostication of gliomas.
Current literature already demonstrates a high sensitivity and
accuracy of individual learning techniques in determining
genetic markers and radiological features. The challenge lies
in creating algorithms that are applicable on much larger
scale, with greater amounts of learning and practice sets for
AI learning techniques to be tested on, while still remaining
logistically feasible to be run within the strict timeframes
within which health-care systems operate. In addition, there
are ethical considerations to be made regarding the use of AI
within the clinical realm and their impact on a physician’s
decision-making.
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